AIR-CF1: Lung Function Clinical Data
CAYSTON significantly improved lung function
CAYSTON demonstrated a significant improvement in FEV1 (L) lung function with a placebo-adjusted treatment effect of 10% (95% CI: 6%, 14%) on Day 28.
Improvements in FEV1 were comparable between adult and pediatric patients1
Two weeks after completion of drug treatment, the difference in FEV1 between CAYSTON and placebo groups had decreased to 6% (95% CI: 2%, 9%).
“When I'm on CAYSTON, I notice a positive difference in my coughing and see a boost in my lung function.”
–Kevin, age 43, TREATED WITH CAYSTON